Changes in immune profiles and platelet function after start TPO-RA in ITP
Recruiting
- Conditions
- Immune thrombocytopenia (ITP)
- Registration Number
- NL-OMON28113
- Lead Sponsor
- MC Utrecht
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
Age 16 years and older
- Previously confirmed diagnosis of primary ITP with current platelet counts of <100x109/L
- Will start treatment with eltrombopag
- Willing and be able to understand the study information and sign the informed consent form.
Exclusion Criteria
- Documented history of persisting severe anemia (defined as hemoglobin <6.0 mmol/L for men and women)
- Treatment with rituximab in the past 9 months
- Treatment with any immune modulating drug other than corticosteroids in the past 3 months
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in immunologic profile and platelet function before start and during treatment with eltrombopag
- Secondary Outcome Measures
Name Time Method Difference in immunologic profile or platelet function at baseline between responding and non-responding patients